Attached To Antibody Or Antibody Fragment Or Immunoglobulin; Derivative Patents (Class 424/1.49)
-
Publication number: 20140248211Abstract: The invention provides a method for treating cancer using a coadministration strategy that combines local codelivery of a therapeutic agent and an intracellular penetration enhancing agent, and optionally in further combination with local administration of an immunotherapeutic agent, such as a cancer vaccine or NKT agonist. The invention also provides a method for treating cancer using an intracellular penetration enhancing agent. The methods of the invention aim to substantially kill and/or destroy the target tumor cells, as well as those cancerous cells that have metastasized to other parts of the body.Type: ApplicationFiled: May 16, 2014Publication date: September 4, 2014Applicant: INTENSITY THERAPEUTICS, INC.Inventor: Lewis H. Bender
-
Publication number: 20140241984Abstract: The invention describes antibodies having a high affinity for aggregated forms of ?-synuclein and a low affinity for monomeric forms of ?-synuclein. The antibodies are useful in the diagnosis of neurodegenerative diseases.Type: ApplicationFiled: December 23, 2013Publication date: August 28, 2014Applicant: UNITED ARAB EMIRATES UNIVERSITYInventor: OMAR EL-AGNAF
-
Publication number: 20140234215Abstract: In one embodiment, a minibody monomer that binds PSMA is provided. The minibody monomer is encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA, an artificial hinge sequence, and a human IgG CH3 sequence. In another embodiment, a CysDB monomer that binds PSMA is provided. The CysDB monomer may be encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA and a cysteine tail. In other embodiments, methods for diagnosing or treating a cancer associated with PSMA expression in a subject are provided.Type: ApplicationFiled: April 30, 2014Publication date: August 21, 2014Applicant: ImaginAb, Inc.Inventors: David T. Ho, Tove Olafsen, Arye Lipman
-
Publication number: 20140234213Abstract: Methods for generating hybrid antibodies are provided.Type: ApplicationFiled: May 29, 2012Publication date: August 21, 2014Inventors: Gregory P. Adams, Heidi H. Simmons, Matthew K. Robinson, Roland Dunbrack, Andreas Lehmann
-
Publication number: 20140234214Abstract: The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods.Type: ApplicationFiled: January 14, 2014Publication date: August 21, 2014Applicant: iPierian, Inc.Inventors: Irene Griswold-Prenner, Nancy E. Stagliano, Vu Dang
-
Patent number: 8808665Abstract: The present application discloses compositions and methods of synthesis and use involving click chemistry reactions for in vivo or in vitro formation of therapeutic and/or diagnostic complexes. Preferably, the diagnostic complex is of use for 18F imaging, while the therapeutic complex is of use for targeted delivery of chemotherapeutic drugs or toxins. More preferably, a chelating moiety or targetable construct may be conjugated to a targeting molecule, such as an antibody or antibody fragment, using a click chemistry reaction involving cyclooctyne, nitrone or azide reactive moieties. In most preferred embodiments, the click chemistry reaction occurs in vivo. In vivo click chemistry is not limited to 18F labeling but can be used for delivering a variety of therapeutic and/or diagnostic agents.Type: GrantFiled: November 18, 2013Date of Patent: August 19, 2014Assignee: Immunomedics, Inc.Inventors: William J. McBride, Christopher A. D'Souza, David M. Goldenberg
-
Publication number: 20140227178Abstract: The present invention concerns compositions and methods of use of humanized anti-HLA-DR antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing CDC or ADCC. In more preferred embodiments, the humanized anti-HLA-DR antibodies bind to the same epitope of HLA-DR as, or compete for binding to HLA-DR with, a murine L243 antibody. Most preferably, the humanized anti-HLA-DR antibody exhibits a higher affinity for HLA-DR than the parental murine antibody. The humanized HLA-DR antibody is of use for therapy of various diseases such as cancer, autoimmune disease or immune dysregulatory function, and is of particular use for therapy of B cell lymphomas and leukemias. In most preferred embodiments, the humanized anti-HLA-DR antibody is capable of inducing at least partial remission of lymphomas that are resistant to other B cell antibodies, such as rituximab.Type: ApplicationFiled: March 25, 2014Publication date: August 14, 2014Applicant: IMMUNOMEDICS, INC.Inventors: David M. Goldenberg, Hans J. Hansen, Chien-Hsing Chang
-
Publication number: 20140227179Abstract: Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to an epitope located within the second to fourth cysteine-rich domains of MUC5ac (amino acid residues 1575-2052) and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay.Type: ApplicationFiled: April 1, 2014Publication date: August 14, 2014Applicant: IMMUNOMEDICS, INC.Inventors: Donglin Liu, David V. Gold, Chien-Hsing Chang, Serengulam V. Govindan, David M. Goldenberg
-
Publication number: 20140227180Abstract: The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6 or less, most preferably 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.Type: ApplicationFiled: April 17, 2014Publication date: August 14, 2014Applicant: Immunomedics, Inc.Inventors: Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg
-
Patent number: 8784772Abstract: The present invention provides a method of treating cancer in a patient (e.g., a human patient) in need thereof, the method comprising administering a therapeutically effective regimen, the regimen comprising administering to a patient in need thereof a compound that targets 67 laminin receptor (67LR). In a particular embodiment, the compound that targets 67LR is an antibody or antibody fragment. In particular, the present invention provides a method of treating cancer comprising administering to a patient in need thereof an antibody that binds to 67LR. The present invention also provides a method of treating cancer comprising administering to a patient in need thereof an antibody conjugate, wherein the antibody conjugate comprises an antibody that binds to 67LR linked to a therapeutic agent, a protein toxin, a cytotoxic agent or other moiety.Type: GrantFiled: March 24, 2008Date of Patent: July 22, 2014Assignee: The Johns Hopkins UniversityInventors: David M. Berman, William Matsui, Xiaobing He
-
Patent number: 8784776Abstract: The present invention relates to diagnostic imaging and in particular to the diagnostic imaging and therapy of cancer by means of compositions which specifically target the FSH Receptor expressed by tumor endothelial cells and circulating blood cells.Type: GrantFiled: February 18, 2009Date of Patent: July 22, 2014Assignees: Inserm (Institut National de la Sante et de la Recherche Medicale), Mount Sinai School of MedicineInventors: Nicolae Ghinea, Aurelian Radu
-
Patent number: 8784819Abstract: Antibodies against influenza hemagglutinin, compositions containing the antibodies, and methods of using the antibodies are provided herein.Type: GrantFiled: September 29, 2010Date of Patent: July 22, 2014Assignee: iBio Inc.Inventors: Vidadi Yusibov, Vadim Mett, Jessica Chichester, Lauren Goldschmidt
-
Publication number: 20140199237Abstract: The present invention relates to antibodies against specific domains of Olfml3 and the use of such in angiogenesis. In particular aspects, angiogenesis-related conditions, such as cancer, can be treated by the composition comprising the Olfml3 antagonists.Type: ApplicationFiled: January 17, 2014Publication date: July 17, 2014Applicant: RESEARCH DEVELOPMENT FOUNDATIONInventors: Beat A. IMHOF, Marijana MILJKOVIC-LICINA, Philipe HAMMEL
-
Publication number: 20140199238Abstract: Antibodies which bind an antigen of the bone marrow neovasculature in leukaemia patients, for use in treatment and diagnosis of leukaemia, in particular the treatment and diagnosis of acute myeloid leukaemia (AML).Type: ApplicationFiled: March 19, 2014Publication date: July 17, 2014Inventors: Manuela Kaspar, Christoph Schliemann, Dario Neri
-
Publication number: 20140199236Abstract: Described herein is the androgen receptor modulator of formula (I) in the treatment of prostate cancer in combination with other therapeutic options and in the treatment of diseases or conditions that are amenable to treatment with the androgen receptor modulator, as well as pharmaceutical compositions and medicaments that include such compound.Type: ApplicationFiled: January 9, 2014Publication date: July 17, 2014Applicant: ARAGON PHARMACEUTICALS, INC.Inventors: ISAN CHEN, JEFFREY H. HAGER, EDNA CHOW MANEVAL, MARK R. HERBERT, NICHOLAS D. SMITH
-
Publication number: 20140193334Abstract: Acridine containing cisplatin compounds have been disclosed that show greater efficacy against cancer than other cisplatin compounds. Methods of delivery of those more effective cisplatin compounds to the nucleus in cancer cells is disclosed using one or more amino acids, one or more sugars, one or more polymeric ethers, C1-6alkylene-phenyl-NH—C(O)—R15, folic acid, ?v?3 integrin RGD binding peptide, tamoxifen, endoxifen, epidermal growth factor receptor, antibody conjugates, kinase inhibitors, diazoles, triazoles, oxazoles, erlotinib, and/or mixtures thereof; wherein R15 is a peptide.Type: ApplicationFiled: August 30, 2012Publication date: July 10, 2014Inventors: Ulrich Bierbach, Song Ding
-
Publication number: 20140193332Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of inflammatory bowel diseases in mammals and to methods of using those compositions of matter for the same.Type: ApplicationFiled: November 4, 2013Publication date: July 10, 2014Applicant: GENENTECH, INC.Inventors: Audrey Goddard, Austin L. Gurney
-
Publication number: 20140193333Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer or pancreatic cancer, for monitoring the effectiveness of acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer or pancreatic cancer treatment, and for drug development. The present invention also provides methods and compositions for depletion of immune cells to treat inflammatory diseases.Type: ApplicationFiled: June 28, 2012Publication date: July 10, 2014Applicant: OXFORD BIOTHERAPEUTICS LTDInventors: Christian Rohlff, Alasdair Stamps
-
Publication number: 20140178299Abstract: A molecular probe for use in detection of cancer cells expressing an Ig superfamily cell adhesion molecule that binds in a homophilic fashion in a subject includes a targeting agent that specifically binds to and/or complexes with a proteolytically cleaved extracellular fragment of the Ig superfamily cell adhesion molecule.Type: ApplicationFiled: February 24, 2014Publication date: June 26, 2014Applicant: Case Western Reserve UniversityInventor: Susann Brady-Kalnay
-
Publication number: 20140178298Abstract: The present invention discloses a method for the enzyme-mediated, site-specific, in-vivo precipitation of a water soluble molecule in an animal. The enzyme is either unique to tumor cells, or is produced within a specific site (e.g., tumor) at concentrations that are higher than that in normal tissues. Alternatively, the enzyme is conjugated to a targeting moiety such as an antibody or a receptor-binding molecule.Type: ApplicationFiled: December 9, 2013Publication date: June 26, 2014Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Amin I. Kassis, Ravi S. Harapanhalli
-
Patent number: 8758723Abstract: The present invention relates generally to the fields of chemistry and radionuclide imaging. More particularly, it concerns compositions, kits and methods for imaging and therapy involving N4 compounds and derivatives.Type: GrantFiled: April 19, 2007Date of Patent: June 24, 2014Assignee: The Board of Regents of the University of Texas SystemInventors: David J. Yang, Chang-Sok Oh, Dong-Fang Yu, Ali Azhdarinia, Saady Kohanim
-
Patent number: 8759297Abstract: Provided herein are compositions for increasing transport of agents across the blood-brain barrier, in some embodiments in both directions, while allowing their activity once across the barrier to remain substantially intact. The agents are transported across the blood-brain barrier via one or more endogenous receptor-mediated transport systems. In some embodiments the agents are therapeutic, diagnostic, or research agent. Also provided herein are nucleic acids encoding proteins contained in the compositions.Type: GrantFiled: August 20, 2007Date of Patent: June 24, 2014Assignee: ArmaGen Technologies, Inc.Inventors: William M. Pardridge, Ruben J. Boado
-
Publication number: 20140170064Abstract: Methods and compositions are provided for labeling proteins with radiohalogen-label reagents. Radiohalogen-labeled proteins may be used for imaging studies, as therapeutics and in diagnostic tests. The [125I] HIP-DOTA label reagent 6 is prepared by an efficient and convenient process.Type: ApplicationFiled: December 18, 2013Publication date: June 19, 2014Applicant: Genentech, Inc.Inventors: Charles Andrew Boswell, Leslie A. Khawli, Jan Marik, Simon Williams
-
Publication number: 20140170065Abstract: The present invention concerns methods and compositions for treatment of HIV infection in a subject. The compositions may comprise a targeting molecule against an HIV antigen, such as an anti-HIV antibody or antibody fragment. The anti-HIV antibody or fragment may be conjugated to a variety of cytotoxic agents, such as doxorubicin. In a preferred embodiment, the antibody or fragment is P4/D10. Other embodiments may concern methods of imaging, detection or diagnosis of HIV infection in a subject using an anti-HIV antibody or fragment conjugated to a diagnostic agent. In alternative embodiments, a bispecific antibody with at least one binding site for an HIV antigen and at least one binding site for a carrier molecule may be administered, optionally followed by a clearing agent, followed by administration of a carrier molecule conjugated to a therapeutic agent.Type: ApplicationFiled: February 24, 2014Publication date: June 19, 2014Applicant: Immunomedics, Inc.Inventors: David M. Goldenberg, Chien-Hsing Chang, Edmund A. Rossi, William J. McBride
-
Publication number: 20140170063Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 ROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.Type: ApplicationFiled: July 23, 2013Publication date: June 19, 2014Inventors: Serengulam V. Govindan, David M. Goldenberg
-
Patent number: 8753610Abstract: The invention provides diagnostic and therapeutic macromolecular compositions that cross the blood-brain barrier, in some embodiments in both directions, while allowing their activity to remain substantially intact once across the barrier. Also provided are methods for using such compositions in the diagnosis or treatment of CNS disorders such as Alzheimer's disease.Type: GrantFiled: April 7, 2010Date of Patent: June 17, 2014Assignee: ArmaGen Technologies, Inc.Inventors: William M. Pardridge, Ruben J. Boado
-
Publication number: 20140161721Abstract: This document provides methods and materials related to genetic variations of developmental disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Autism Spectrum Disorder.Type: ApplicationFiled: February 8, 2013Publication date: June 12, 2014Inventors: Eli Hatchwell, Peggy S. Eis, Stephen Scherer, Aparna Prasad
-
Publication number: 20140161722Abstract: The present invention relates to the use of compounds of formula (I) in the treatment of Epidermal Growth Factor Receptor (EGFR) family members dependent diseases or diseases that have acquired resistance to agents that target EGFR family members, use of said compounds for the manufacture of pharmaceutical compositions for the treatment of said diseases, combinations of said compounds with EGFR modulators for said use, methods of treating said diseases with said compounds and pharmaceutical preparations for the treatment of said diseases comprising said compounds alone or in combination, especially with an EGFR modulator.Type: ApplicationFiled: February 17, 2014Publication date: June 12, 2014Applicant: NOVARTIS AGInventors: Carlos Garcia-Echeverria, Maira Sauveur-Michel
-
Publication number: 20140154238Abstract: Compositions and methods which inhibit the expression of the TMEM92 gene or which inhibits the function of die TMEM92 protein can be used for treating, diagnosing and monitoring disease, for example cancer.Type: ApplicationFiled: March 28, 2012Publication date: June 5, 2014Applicant: Hox Therapeutics LimitedInventor: Richard Morgan
-
Publication number: 20140147383Abstract: Antibodies that bind to a GPR49 protein and have cell proliferation inhibitory activity against cells expressing the GPR49 protein are disclosed. Cell proliferation inhibitory activities are cytotoxic activities such as antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. Pharmaceutical compositions, cell-proliferation inhibitors, and anticancer agents containing an antibody of the present invention as an active ingredient are also disclosed. Examples of cancer include gastric cancer, colon cancer, hepatocellular carcinoma, lung cancer, prostate cancer, ovarian cancer, Ewing's sarcoma, and glioma. Furthermore, methods for diagnosing cancer by detecting expression of a GPR49 protein or a gene encoding a GPR49 protein, and diagnostic agents and kits to be used in these methods are also disclosed.Type: ApplicationFiled: February 5, 2014Publication date: May 29, 2014Applicant: Chugai Seiyaku Kabushiki KaishaInventor: Shinichi FUNAHASHI
-
Publication number: 20140147382Abstract: The invention is directed to a method for treating a treating and diagnosing a B cell-related disease, T cell-related disease or an autoimmune disease in a mammal by concurrently or sequentially administering to the mammal a therapeutic composition that comprises a pharmaceutically acceptable vehicle and at least one conjugated antibody, wherein predosing with a non-radiolabeled antibody is not performed.Type: ApplicationFiled: January 30, 2014Publication date: May 29, 2014Applicant: IMMUNOMEDICS, INC.Inventors: David M. GOLDENBERG, Hans HANSEN
-
Publication number: 20140140924Abstract: Humanized antibodies are provided that specifically bind HLA-DR. The antibodies recognize the epitope recognized by the murine monoclonal antibody L243. Processes for preparing such antibodies, pharmaceutical compositions containing such antibodies, and clinical therapeutic and diagnostic, as well as research-related uses for such antibodies, are provided.Type: ApplicationFiled: November 14, 2013Publication date: May 22, 2014Applicant: IMMUNOMEDICS, INC.Inventors: David M. Goldenberg, Hans J. Hansen, Zhengxing Qu, Chien-Hsing Chang
-
Patent number: 8728477Abstract: The present invention is directed to monoclonal, chimeric or humanized, antibodies or antibody-like molecules that recognize an epitope common to human acidic and basic isoferritins. The anti-ferritin antibodies or antibody-like molecules can be used in pharmaceutical compositions for immunotherapy or radioimmunotherapy to target various cancer cells in a mammal. A method for delivering anti-ferritin antibodies or antibody-like molecules to cancerous lymph cells, pancreatic cells, lymphatic endothelium cells, and liver cells is also disclosed, as well as methods for treating pancreatic cancer, hepatocellular carcinomas, Kaposi's sarcoma and Hodgkin's lymphoma.Type: GrantFiled: September 19, 2007Date of Patent: May 20, 2014Assignee: Immune Pharmaceuticals Ltd.Inventors: Jean Kadouche, Emmanuelle Sabbah-Petrover, Olivier Chose
-
Publication number: 20140134103Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.Type: ApplicationFiled: December 6, 2013Publication date: May 15, 2014Applicants: University of Tennessee Research Foundation, Elan Pharmaceuticals, Inc.Inventors: Dale B. SCHENK, Peter A. Seubert, Jonathan Wall, José Saldanha
-
Patent number: 8715619Abstract: The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.Type: GrantFiled: February 11, 2013Date of Patent: May 6, 2014Assignee: Cellerant Therapeutics, Inc.Inventor: Holger Karsunky
-
Publication number: 20140120035Abstract: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.Type: ApplicationFiled: September 27, 2013Publication date: May 1, 2014Applicant: IMMUNOMEDICS, INC.Inventors: Serengulam V. Govindan, Zhengxing Qu, Hans J. Hansen, David M. Goldenberg
-
Publication number: 20140112865Abstract: The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a Ser91Phe substitution in the hA19 VH sequence.Type: ApplicationFiled: November 22, 2013Publication date: April 24, 2014Applicant: IMMUNOMEDICS, INC.Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
-
Publication number: 20140112864Abstract: Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to pancreatic cancer mucins such as MUC1 or MUC5ac and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay. Alternatively, immunoassay with PAM4 and anti-CA19.9 antibodies may be utilized to improve sensitivity for pancreatic cancer.Type: ApplicationFiled: September 25, 2013Publication date: April 24, 2014Applicant: IMMUNOMEDICS, INC.Inventors: David V. Gold, David M. Goldenberg
-
Publication number: 20140105819Abstract: The present application discloses compositions and methods of synthesis and use involving click chemistry reactions for in vivo or in vitro formation of therapeutic and/or diagnostic complexes. Preferably, the diagnostic complex is of use for 18F imaging, while the therapeutic complex is of use for targeted delivery of chemotherapeutic drugs or toxins. More preferably, a chelating moiety or targetable construct may be conjugated to a targeting molecule, such as an antibody or antibody fragment, using a click chemistry reaction involving cyclooctyne, nitrone or azide reactive moieties. In most preferred embodiments, the click chemistry reaction occurs in vivo. In vivo click chemistry is not limited to 18F labeling but can be used for delivering a variety of therapeutic and/or diagnostic agents.Type: ApplicationFiled: November 18, 2013Publication date: April 17, 2014Applicant: IMMUNOMEDICS, INC.Inventors: William J. McBride, Christopher A. D'Souza, David M. Goldenberg
-
Publication number: 20140099258Abstract: The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates.Type: ApplicationFiled: November 13, 2013Publication date: April 10, 2014Applicant: IMMUNOMEDICS, INC.Inventors: Serengulam V. Govindan, David M. Goldenberg, Sung-Ju Moon
-
Publication number: 20140099259Abstract: The invention relates to recognition molecules which are directed towards tumors and can be used in the diagnosis and therapy of tumor diseases.Type: ApplicationFiled: December 10, 2013Publication date: April 10, 2014Applicant: Glycotope GmbHInventors: Steffen Goletz, Antje Danielczyk, Uwe Karsten, Peter Ravn, Renate Stahn, Peter Astrup Christensen
-
Publication number: 20140099257Abstract: Anti-androgen therapies represent the cornerstone of prostate cancer (PC) treatment. Yet all PC patients ultimately fail efforts to rein in the androgen receptor (AR). This invention is based on the discovery that prostate-specific membrane antigen (PSMA), a highly PC-specific and clinically validated cell surface target, is AR-suppressed and up-regulated in PC as a result of hormonal manipulation. This up-regulation occurs in an unexpected timeframe and it occurs even in the castrate-resistant setting. As a result, hormonal therapy creates a state of conditionally enhanced vulnerability of PC to PSMA-targeted anti-cancer/cytotoxic agents that can be exploited by leveraging anti-AR therapy by the addition of PSMA-targeted agents. We demonstrate this conditionally enhanced vulnerability in a castrate-resistant animal model. The state of conditionally enhanced vulnerability may be relevant for other cancer targets and efforts to screen for them may improve other cancer therapies.Type: ApplicationFiled: March 14, 2013Publication date: April 10, 2014Applicant: CORNELL UNIVERSITYInventor: Neil H. BANDER
-
Publication number: 20140093449Abstract: Analogs of largazole are described herein. Methods of treating cancer and blood disorders using largazole and largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described.Type: ApplicationFiled: July 17, 2013Publication date: April 3, 2014Applicants: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION, UNIVERSITY OF NOTRE DAME DU LAC, DANA-FARBER CANCER INSTITUTE, INC.Inventors: Robert M. Williams, James E. Bradner, Albert Bowers, Tenaya Newkirk, Olaf G. Wiest
-
Publication number: 20140086830Abstract: The present invention provides compositions and methods of use of anti-IGF-1R antibodies or antibody fragments. Preferably the antibodies bind to IGF-1R but not IR; are not agonists for IGF-1R; do not block binding of IGF-1 or IGF-2 to isolated IGF-1R, but effectively neutralize activation of IGF-1R by IGF-1 in intact cells; and block binding of an R1 antibody to IGF-1R. The antibodies may be murine, chimeric, humanized or human R1 antibodies comprising the heavy chain CDR sequences DYYMY (SEQ ID NO:1), YITNYGGSTYYPDTVKG (SEQ ID NO:2) and QSNYDYDGWFAY (SEQ ID NO:3) and the light chain CDR sequences KASQEVGTAVA (SEQ ID NO:4), WASTRHT (SEQ ID NO:5) and QQYSNYPLT (SEQ ID NO:6). Preferably the antibodies bind to an epitope of IGF-1R comprising the first half of the cysteine-rich domain of IGF-1R (residues 151-222). The anti-IGF-1R antibodies may be used for diagnosis or therapy of various diseases such as cancer.Type: ApplicationFiled: October 23, 2013Publication date: March 27, 2014Applicant: IMMUNOMEDICS, INC.Inventors: Chien-Hsing Chang, Michele J. Losman, David M. Goldenberg
-
Publication number: 20140086829Abstract: The present invention reveals human recombinant antibodies that recognize the human Vascular Endothelium Growth Factor A (VEGF-A), block its interaction with the VEGFR2 receptor, and interfere with its proliferative effect in vitro and pro-angiogenic effect in vivo. The antibodies identify an epitope on human VEGF-A different from any other previously reported, and were obtained by combining one immunoglobulin light chain variable region with other three heavy chain ones. The antibodies were obtained by human immunoglobulin variable region mutagenesis, and can be employed for the immunotherapy of pathological entities associated with to an increase in vasculature, such as age-related macular degeneration, cancer, and others.Type: ApplicationFiled: December 26, 2011Publication date: March 27, 2014Applicants: BIOREC S.A., CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Humberto Lamdan Ordas, Jorge Victor Gavilondo Cowley, Marta Ayala Avila, Yasmiana Munoz Pozo, Amaury Pupo Merino, Gertrudis Rojas Dorantes, Lincidio Perez Sanchez
-
Publication number: 20140079629Abstract: The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.Type: ApplicationFiled: October 29, 2013Publication date: March 20, 2014Applicant: IMMUNOMEDICS, INC.Inventors: Hans J. Hansen, Chien-Hsing Chang, David M. Goldenberg
-
Publication number: 20140065065Abstract: An embodiment of the invention comprises method of imaging a target site comprising administrating ligand of Formula I complexed to 99mTc wherein R1 and R2 are independently an alkyl or cycloalkyl; R3 is and alkyl; X is CO or SO2; Y is (CH2)n, C6H4, (OCH2CH2)n (NHCH2CH2)n and (OCH2CH2CH2)n, or a combination thereof; Z is linker group capable of conjugating to a vector; and n is an integer between 0 and 10.Type: ApplicationFiled: November 6, 2013Publication date: March 6, 2014Applicant: GENERAL ELECTRIC COMPANYInventors: Bruce Fletcher Johnson, Randall Lee Carter, Michael James Rishel, Mark Christopher Patrick Darey, Tao Wu, Yang Yang, John Fitzmaurice Valliant, Karin Ann Stephenson
-
Publication number: 20140065063Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.Type: ApplicationFiled: May 15, 2013Publication date: March 6, 2014Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
-
Publication number: 20140065064Abstract: Monoclonal antibodies (MoAbs or mAbs) specific for ALPHA-ACTININ-4 antigens, hybridoma lines that secrete these ALPHA-ACTININ-4 mAbs, and the use of such mAbs to detect ALPHA-ACTININ-4 antigens, particularly those expressed by cancer cells are disclosed. Chimeric and humanized antibodies based upon these anti-ALPHA-ACTININ-4 mAbs, processes for producing monoclonal, chimeric, and humanized antibodies using recombinant DNA technology, and their therapeutic uses, particularly in the treatment of cancer are also disclosed. Methods and kits for the immunodetection and immunotherapy of cells for samples which express ALPHA-ACTININ-4 antigens are additionally disclosed.Type: ApplicationFiled: December 23, 2011Publication date: March 6, 2014Inventor: Özge Alper
-
Patent number: 8663598Abstract: One embodiment of the disclosure provides an amino sequence of an anti-human transferrin receptor antibody, including: an amino sequence of a heavy chain variable region which is represented by SEQ ID NO.: 1 or SEQ ID NO.: 2, wherein the anti-human transferrin receptor antibody is capable of specifically binding to a human transferrin receptor.Type: GrantFiled: September 11, 2012Date of Patent: March 4, 2014Assignee: Industrial Technology Research InstituteInventors: Ming-Hua Yang, Min-Yuan Chou, Hsiang-Ching Wang